Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
WASHINGTON, DC--(Marketwire - Dec 28, 2011) - Judicial Watch, the public interest group that investigates and prosecutes government corruption, today released its 2011 list of Washington's "Ten...
-
NEW YORK, Dec. 16, 2011 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight lethal disease-causing pathogens,...
-
NEW YORK--Synergy Pharmaceuticals, Inc. (Nasdaq:SGYPD, SGYPU), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, announced today that it has filed a lawsuit in New York...
-
VANCOUVER, British Columbia, Nov. 16, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, disclosed today...
-
LAVAL, Quebec, Sept. 28, 2011 (GLOBE NEWSWIRE) -- Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation") (Nasdaq:NEPT) (TSX-V:NTB) is proud to announce that Omnikrill (100%...
-
LOS ANGELES, June 15, 2011 (GLOBE NEWSWIRE) -- With the recent U.S. Supreme Court ruling on overcrowding in California's prisons, CompuMed Inc. (Pink Sheets:CMPD) (http://www.compumed.net) President...
-
Genmab A/S 15.03.2011 15:57 --------------------------------------------------------------------------- -- Genmab A/S to hold Annual general Meeting on April 6, 2011 Copenhagen, Denmark; March...
-
NEW YORK, Aug. 4, 2009 (GLOBE NEWSWIRE) -- Seeger Weiss LLP, one of the nation's premier plaintiffs' law firms, announces that founding member Christopher A. Seeger has obtained an agreement in...
-
H. Lundbeck A/S reports highest ever quarterly revenue of DKK 3,226 million, a growth of 15% in constant exchange rates, driven by strong growth in Cipralex®, Ebixa® and Azilect®. The divestment of...
-
- Revenue generated in 2008 is the highest ever in Lundbeck's history - Growth driven by double-digit growth rates for Cipralex®, Ebixa® and Azilect® - Lundbeck meets all of...